REGULATORY

Japan Prepping to Expand Veklury Label beyond Severe COVID-19: PMDA

December 25, 2020

- Only subscribers can save articles.
  
  Sign In
  
  Subscribe

Japanese regulators are preparing to expand the label of Gilead Sciences’ antiviral agent Veklury (remdesivir) to allow its use beyond severely ill patients with COVID-19 in alignment with the population of patients in whom the drug’s efficacy and safety were…

To read the full story

PMDA Updates Veklury Label to Allow Its Use in Moderate COVID-19
January 8, 2021

REGULATORY

Japan Panel Backs Daiichi’s MMR Vaccine, Haihe’s PI3Kα Inhibitor, MSD’s HIV Med
March 3, 2026
MHLW Revises Guidance on Pediatric Development Plans under Amended PMD Act
March 3, 2026
MHLW Details New Operational Rules for Conditional Approvals from May
March 3, 2026
MHLW Seeks Sponsors to Develop 8 “Drug-Loss” Products
March 2, 2026
WG Members Urge Domestic Biologic Production as National Growth Strategy
March 2, 2026

Chuikyo Debate on FY2026 Drug Pricing Reform

Chuikyo OKs New CEA Handling, with Third-Party Verification Ahead

Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…

COMMENTARY

G1 Rule to Hit Originator Biologics for First Time, Impact Seen for Up to 13 Brands

By Shinya Sato

Japan’s FY2026 drug pricing reform will, for the first time, apply the “G1” price cut rule for long-listed original biologics…

COLUMN

The Strategic MSL: Beyond Data Delivery, It’s About Impact

By Philip Carrigan

I recently sat down with one of the leading medical directors in Japan to discuss the critical evolution of the medical science liaison (MSL) role.The MSL has transformed from a scientific resource into a strategic partner essential for successful product…